CT-Based Commercial Software Applications: Improving Patient Care Through Accurate COPD Subtyping.
Jennifer M WangSundaresh RamWassim W LabakiMeilan K HanCraig J GalbanPublished in: International journal of chronic obstructive pulmonary disease (2022)
Chronic obstructive pulmonary disease (COPD) is heterogenous in its clinical manifestations and disease progression. Patients often have disease courses that are difficult to predict with readily available data, such as lung function testing. The ability to better classify COPD into well-defined groups will allow researchers and clinicians to tailor novel therapies, monitor their effects, and improve patient-centered outcomes. Different modalities of assessing these COPD phenotypes are actively being studied, and an area of great promise includes the use of quantitative computed tomography (QCT) techniques focused on key features such as airway anatomy, lung density, and vascular morphology. Over the last few decades, companies around the world have commercialized automated CT software packages that have proven immensely useful in these endeavors. This article reviews the key features of several commercial platforms, including the technologies they are based on, the metrics they can generate, and their clinical correlations and applications. While such tools are increasingly being used in research and clinical settings, they have yet to be consistently adopted for diagnostic work-up and treatment planning, and their full potential remains to be explored.
Keyphrases
- lung function
- chronic obstructive pulmonary disease
- computed tomography
- cystic fibrosis
- air pollution
- dual energy
- image quality
- end stage renal disease
- contrast enhanced
- positron emission tomography
- chronic kidney disease
- newly diagnosed
- machine learning
- high resolution
- big data
- type diabetes
- palliative care
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- high throughput
- magnetic resonance
- adipose tissue
- climate change
- insulin resistance